INVA vs. OPK, MNKD, IRWD, LGND, PHAT, KNSA, TBPH, LXRX, DVAX, and VNDA
Should you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include OPKO Health (OPK), MannKind (MNKD), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), Phathom Pharmaceuticals (PHAT), Kiniksa Pharmaceuticals (KNSA), Theravance Biopharma (TBPH), Lexicon Pharmaceuticals (LXRX), Dynavax Technologies (DVAX), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Innoviva (NASDAQ:INVA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
99.1% of Innoviva shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 1.4% of Innoviva shares are owned by company insiders. Comparatively, 47.3% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, OPKO Health had 10 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for OPKO Health and 1 mentions for Innoviva. Innoviva's average media sentiment score of 0.00 beat OPKO Health's score of -0.67 indicating that Innoviva is being referred to more favorably in the media.
Innoviva has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.
Innoviva has a net margin of 57.89% compared to OPKO Health's net margin of -21.76%. Innoviva's return on equity of 30.37% beat OPKO Health's return on equity.
OPKO Health received 203 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 65.87% of users gave OPKO Health an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
OPKO Health has a consensus price target of $3.17, suggesting a potential upside of 153.33%. Given OPKO Health's higher probable upside, analysts plainly believe OPKO Health is more favorable than Innoviva.
Innoviva has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Summary
Innoviva beats OPKO Health on 9 of the 17 factors compared between the two stocks.
Get Innoviva News Delivered to You Automatically
Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innoviva Competitors List
Related Companies and Tools
